OncoMatch/Clinical Trials/NCT05870995
Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia
Is NCT05870995 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies CALGE-VEN- RIC-conditioning for refractory leukemia.
Treatment: CALGE-VEN- RIC-conditioning — The investigators developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide (CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu to treat patients with refractory acute myeloid leukemia (AML). In this study, the aim is to further evaluate the efficacy and feasibility of the protocol with modifications: 1) reduced dose of CLAGE; 2) Reduced intensity conditioning (RIC) regimen as fludarabine, busulfan and melphalan (MBF) or total marrow irradiation (TMI); 3) Venetoclax was added to the chemotherapy and conditioning regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Demographics
Lab requirements
Kidney function
abnormal renal function (Scr >1.5N) excluded
Liver function
abnormal liver function (enzyme >2N or bilirubin >2N) excluded
Cardiac function
poor cardiac function (EF<45%) excluded
patients with abnormal liver function (enzyme >2N or bilirubin >2N); patients with abnormal renal function (Scr >1.5N); patients with poor cardiac function （EF<45%）
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05870995 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 16 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify